Generic medications for hepatitis C
The recent development and approval of expensive but highly effective oral agents against hepatitis C has led to restrictions and access limitations in many countries with limited healthcare budgets. Generic formulations of many of these agents are available at a fraction of the retail price in seve...
Gespeichert in:
| Veröffentlicht in: | Liver international 2016-07, Vol.36 (7), p.925-928 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 928 |
|---|---|
| container_issue | 7 |
| container_start_page | 925 |
| container_title | Liver international |
| container_volume | 36 |
| creator | Jensen, Donald M. Sebhatu, Phoebe Reau, Nancy S. |
| description | The recent development and approval of expensive but highly effective oral agents against hepatitis C has led to restrictions and access limitations in many countries with limited healthcare budgets. Generic formulations of many of these agents are available at a fraction of the retail price in several countries because of generic licensure agreements. The discounted alternatives are only accessible in developing countries and require manufacturing and distribution regulations to ensure the quality and bioequivalence of the new drug formulations. The continued medication access limitations have driven great interest in the practice of personal drug importation of the generic formulations. This review and debate will address the medical and legal issues involved in the purchase and importation of these medicines. |
| doi_str_mv | 10.1111/liv.13120 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1797878121</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1797878121</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3630-5261a0cd0cf2286b760d42dd65fdf98a096ae9c1fdc6450f45c67df6f56452673</originalsourceid><addsrcrecordid>eNp1kD1PwzAQhi0EolAY-AMoEgsMaf0R28mIKmgLARagEovl-kMY0qbYKdB_jyFtN265O-m5R7oXgBMEeyhWv3KfPUQQhjvgAGU8TwkmaHc7Y9IBhyG8QYiKgqJ90MGcQEYgPgBnQzM33qlkZrRTsnH1PCS29smrWcStcSEZHIE9K6tgjte9C56urx4Ho7R8GI4Hl2WqSJSlFDMkodJQWYxzNuUM6gxrzajVtsglLJg0hUJWK5ZRaDOqGNeWWRpXzDjpgvPWu_D1x9KERsxcUKaq5NzUyyAQL3jOc4RRRC9aVPk6BG-sWHg3k34lEBS_mYiYifjLJLKna-1yGr_ckpsQItBvgS9XmdX_JlGOnzfKtL1woTHf2wvp30X8g1MxuR8KPLl7uR3hG1GSHz9VeAg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1797878121</pqid></control><display><type>article</type><title>Generic medications for hepatitis C</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Jensen, Donald M. ; Sebhatu, Phoebe ; Reau, Nancy S.</creator><creatorcontrib>Jensen, Donald M. ; Sebhatu, Phoebe ; Reau, Nancy S.</creatorcontrib><description>The recent development and approval of expensive but highly effective oral agents against hepatitis C has led to restrictions and access limitations in many countries with limited healthcare budgets. Generic formulations of many of these agents are available at a fraction of the retail price in several countries because of generic licensure agreements. The discounted alternatives are only accessible in developing countries and require manufacturing and distribution regulations to ensure the quality and bioequivalence of the new drug formulations. The continued medication access limitations have driven great interest in the practice of personal drug importation of the generic formulations. This review and debate will address the medical and legal issues involved in the purchase and importation of these medicines.</description><identifier>ISSN: 1478-3223</identifier><identifier>EISSN: 1478-3231</identifier><identifier>DOI: 10.1111/liv.13120</identifier><identifier>PMID: 27306302</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Antiviral Agents - economics ; Antiviral Agents - therapeutic use ; Canada ; Commerce - legislation & jurisprudence ; counterfeit ; Counterfeit Drugs ; Drug and Narcotic Control ; Drug Approval ; Drugs, Generic - economics ; Drugs, Generic - therapeutic use ; Fraud ; generic ; hepatitis C ; Hepatitis C - drug therapy ; Humans ; Quality Control ; regulations ; Safety ; United States ; United States Food and Drug Administration</subject><ispartof>Liver international, 2016-07, Vol.36 (7), p.925-928</ispartof><rights>2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3630-5261a0cd0cf2286b760d42dd65fdf98a096ae9c1fdc6450f45c67df6f56452673</citedby><cites>FETCH-LOGICAL-c3630-5261a0cd0cf2286b760d42dd65fdf98a096ae9c1fdc6450f45c67df6f56452673</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fliv.13120$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fliv.13120$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27306302$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jensen, Donald M.</creatorcontrib><creatorcontrib>Sebhatu, Phoebe</creatorcontrib><creatorcontrib>Reau, Nancy S.</creatorcontrib><title>Generic medications for hepatitis C</title><title>Liver international</title><addtitle>Liver Int</addtitle><description>The recent development and approval of expensive but highly effective oral agents against hepatitis C has led to restrictions and access limitations in many countries with limited healthcare budgets. Generic formulations of many of these agents are available at a fraction of the retail price in several countries because of generic licensure agreements. The discounted alternatives are only accessible in developing countries and require manufacturing and distribution regulations to ensure the quality and bioequivalence of the new drug formulations. The continued medication access limitations have driven great interest in the practice of personal drug importation of the generic formulations. This review and debate will address the medical and legal issues involved in the purchase and importation of these medicines.</description><subject>Antiviral Agents - economics</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Canada</subject><subject>Commerce - legislation & jurisprudence</subject><subject>counterfeit</subject><subject>Counterfeit Drugs</subject><subject>Drug and Narcotic Control</subject><subject>Drug Approval</subject><subject>Drugs, Generic - economics</subject><subject>Drugs, Generic - therapeutic use</subject><subject>Fraud</subject><subject>generic</subject><subject>hepatitis C</subject><subject>Hepatitis C - drug therapy</subject><subject>Humans</subject><subject>Quality Control</subject><subject>regulations</subject><subject>Safety</subject><subject>United States</subject><subject>United States Food and Drug Administration</subject><issn>1478-3223</issn><issn>1478-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kD1PwzAQhi0EolAY-AMoEgsMaf0R28mIKmgLARagEovl-kMY0qbYKdB_jyFtN265O-m5R7oXgBMEeyhWv3KfPUQQhjvgAGU8TwkmaHc7Y9IBhyG8QYiKgqJ90MGcQEYgPgBnQzM33qlkZrRTsnH1PCS29smrWcStcSEZHIE9K6tgjte9C56urx4Ho7R8GI4Hl2WqSJSlFDMkodJQWYxzNuUM6gxrzajVtsglLJg0hUJWK5ZRaDOqGNeWWRpXzDjpgvPWu_D1x9KERsxcUKaq5NzUyyAQL3jOc4RRRC9aVPk6BG-sWHg3k34lEBS_mYiYifjLJLKna-1yGr_ckpsQItBvgS9XmdX_JlGOnzfKtL1woTHf2wvp30X8g1MxuR8KPLl7uR3hG1GSHz9VeAg</recordid><startdate>201607</startdate><enddate>201607</enddate><creator>Jensen, Donald M.</creator><creator>Sebhatu, Phoebe</creator><creator>Reau, Nancy S.</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201607</creationdate><title>Generic medications for hepatitis C</title><author>Jensen, Donald M. ; Sebhatu, Phoebe ; Reau, Nancy S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3630-5261a0cd0cf2286b760d42dd65fdf98a096ae9c1fdc6450f45c67df6f56452673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antiviral Agents - economics</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Canada</topic><topic>Commerce - legislation & jurisprudence</topic><topic>counterfeit</topic><topic>Counterfeit Drugs</topic><topic>Drug and Narcotic Control</topic><topic>Drug Approval</topic><topic>Drugs, Generic - economics</topic><topic>Drugs, Generic - therapeutic use</topic><topic>Fraud</topic><topic>generic</topic><topic>hepatitis C</topic><topic>Hepatitis C - drug therapy</topic><topic>Humans</topic><topic>Quality Control</topic><topic>regulations</topic><topic>Safety</topic><topic>United States</topic><topic>United States Food and Drug Administration</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jensen, Donald M.</creatorcontrib><creatorcontrib>Sebhatu, Phoebe</creatorcontrib><creatorcontrib>Reau, Nancy S.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Liver international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jensen, Donald M.</au><au>Sebhatu, Phoebe</au><au>Reau, Nancy S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Generic medications for hepatitis C</atitle><jtitle>Liver international</jtitle><addtitle>Liver Int</addtitle><date>2016-07</date><risdate>2016</risdate><volume>36</volume><issue>7</issue><spage>925</spage><epage>928</epage><pages>925-928</pages><issn>1478-3223</issn><eissn>1478-3231</eissn><abstract>The recent development and approval of expensive but highly effective oral agents against hepatitis C has led to restrictions and access limitations in many countries with limited healthcare budgets. Generic formulations of many of these agents are available at a fraction of the retail price in several countries because of generic licensure agreements. The discounted alternatives are only accessible in developing countries and require manufacturing and distribution regulations to ensure the quality and bioequivalence of the new drug formulations. The continued medication access limitations have driven great interest in the practice of personal drug importation of the generic formulations. This review and debate will address the medical and legal issues involved in the purchase and importation of these medicines.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>27306302</pmid><doi>10.1111/liv.13120</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-3223 |
| ispartof | Liver international, 2016-07, Vol.36 (7), p.925-928 |
| issn | 1478-3223 1478-3231 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1797878121 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Antiviral Agents - economics Antiviral Agents - therapeutic use Canada Commerce - legislation & jurisprudence counterfeit Counterfeit Drugs Drug and Narcotic Control Drug Approval Drugs, Generic - economics Drugs, Generic - therapeutic use Fraud generic hepatitis C Hepatitis C - drug therapy Humans Quality Control regulations Safety United States United States Food and Drug Administration |
| title | Generic medications for hepatitis C |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T02%3A08%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Generic%20medications%20for%20hepatitis%20C&rft.jtitle=Liver%20international&rft.au=Jensen,%20Donald%20M.&rft.date=2016-07&rft.volume=36&rft.issue=7&rft.spage=925&rft.epage=928&rft.pages=925-928&rft.issn=1478-3223&rft.eissn=1478-3231&rft_id=info:doi/10.1111/liv.13120&rft_dat=%3Cproquest_cross%3E1797878121%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1797878121&rft_id=info:pmid/27306302&rfr_iscdi=true |